Sedana Medical AB (publ), interim report Q1, 2020
Regulatory
Hard work to meet the intensive care needs during COVID-19
Notice of Annual General Meeting in Sedana Medical AB (publ)
Regulatory
The shareholders in Sedana Medical AB (publ), reg. no. 556670-2519, are hereby given notice to attend the annual general meeting on Tuesday 19 May 2020 at 4:00 p.m. (CEST) at Konferens Spårvagnshallarna, Birger Jarlsgatan 57 A in Stockholm. Registrat…
The nomination committee's resolution proposals for election of board members etc. at the annual general meeting in Sedana Medical
Regulatory
The nomination committee of Sedana Medical AB (publ) (SEDANA: FN Stockholm) has presented its resolution proposals for the annual general meeting 19 May 2020. The nomination committee’s proposals include, inter alia, re-election of all current ordina…
Sedana Medical's sales increase around 90 percent
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company expects sales of approximately SEK 34 million in the first quarter of 2020, corresponding to growth of around 90 percent compared to the same period last year.
Sedana Medical sees increased demand and keeps time schedule
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company sees increased demand for AnaConDa as a result of the Covid-19 pandemic and so far, has had no significant supply chain disruptions. Sedana Medical forecasts a sales inc…
AnaConDa e-learning released to meet increased inquiries related to COVID-19
Non-regulatory
As a response to an increased amount of inquiries, Sedana Medical has decided to release an e-learning to educate healthcare professionals in the practical use of the AnaConDa.
Sedana Medical Research Grant 2020 open for applications
Non-regulatory
Sedana Medical AB (publ) today announced the opening for researchers to apply for Sedana Medical Research Grant 2020. The grant creates a unique opportunity for the scientific community to increase knowledge of sedation therapies of critically ill pa…
Sedana Medical AB (publ), Year-end report, 2019
Regulatory
Another strong quarter with increased sales growth
Sedana Medical donates AnaConDa to hospitals in Wuhan, China
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company is donating the medical device AnaConDa and accessories for anti-epidemic use and evaluation of the effects of inhalation sedation with AnaConDa on severely ill Corona v…
Sedana Medical establishes sales organization in Benelux
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has set up its own direct sales organization in Benelux, in line with the strategy of being represented in several European markets in order to have well-established net…
Sedana Medical receives approval for AnaConDa in Mexico
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has obtained market approval for AnaConDa in Mexico. Sedana Medical's Mexican distributor Goba will begin sales work in the next few months and in parallel Sedana will e…
Sedana Medical’s CEO divests shares – remains committed and long-term shareholder
Non-regulatory
Christer Ahlberg, CEO of Sedana Medical AB, has informed the Company that he has sold 30 000 shares in Sedana Medical, representing approximately 0.1% of total outstanding shares and 13.0% of his total shareholding in the Company, and that he has ent…
Last patient included in Sedana Medical's pivotal IsoConDa study
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the last patient has now been included in the pivotal IsoConDa study. Thus, all 300 patients have been included and the study is expected to show top-line results during Q2 2020.
Sedana Medical supports isoflurane sedation study for reduction of delirium
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company is funding a large French multicenter study with isoflurane – the substance in the company´s drug candidate IsoConDa – delivered by the company’s medical device AnaConDa…
Sedana Medical AB (publ), Interim report Q3, 2019
Regulatory
Strong sales growth and good progress towards registration
Sedana Medical’s board member Michael Ryan resigns
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that Michael Ryan is retiring and therefore is resigning from the company’s board of directors.
Sedana Medical adjusts and clarifies its long-term financial targets
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company will no longer communicate a profit target for the period until registration of IsoConDa in Europe. It also clarifies the sales target of SEK 500 million three years aft…
Sedana Medical’s nomination committee appointed
Non-regulatory
Sedana Medical AB (publ) today publish that in accordance with the resolution of the Annual General Meeting on May 28, 2019, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes t…
Sedana Medical is co-funding AnaConDa study on lung protection
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company is co-financing the world's largest multicenter study with AnaConDa in France. The primary purpose of the study is to show that inhaled sedation with AnaConDa has lung p…